Artificial Intelligence In Precision Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Component, By Therapeutic Application, By Region & Competition, 2021-2031F

The Global Artificial Intelligence in Precision Medicine Market is poised for significant expansion, projected to grow from USD 1.78 Billion in 2025 to USD 3.12 Billion by 2031, demonstrating a robust 9.81% Compound Annual Growth Rate. This growth is driven by the application of advanced computational algorithms, notably machine learning and deep learning, to analyze complex biological and clinical data. Such applications enable the precise customization of healthcare interventions, medical decisions, and treatments, tailoring them to each patient's unique genetic makeup, lifestyle, and environmental factors.

Key market drivers include the rapid proliferation of large-scale genomic data, the urgent economic need to curtail high drug discovery costs, and the rising global incidence of chronic diseases demanding targeted therapies. For example, the American Medical Association reported in 2025 that 66% of physicians were utilizing healthcare artificial intelligence in 2024, marking a substantial increase in adoption. However, despite this positive momentum, the market faces considerable challenges, particularly concerning data privacy and security, as the handling of sensitive patient information necessitates navigating complex regulatory hurdles that could impede broader market penetration.

Market Driver

A primary force propelling the adoption of artificial intelligence in precision medicine is the urgent need for cost containment and enhanced efficiency within healthcare delivery systems. Faced with escalating financial pressures, healthcare organizations are increasingly implementing AI solutions to automate administrative tasks and optimize resource allocation. These technologies not Monly streamline operations, allowing providers to concentrate more on patient care, but also significantly reduce expenditures. As evidenced by NVIDIA's March 2025 "State of AI in Healthcare and Life Sciences" report, 73% of organizations identified reductions in operating costs as a key benefit of AI integration, with this efficiency extending to clinical settings for tasks such as validating diagnostic results and more effectively stratifying patient risks.

Furthermore, the acceleration of drug discovery and development timelines is fundamentally reshaping the precision medicine landscape by addressing the inherent inefficiencies of traditional pharmaceutical research and development. While conventional methods often require over a decade to bring a new therapy to market, AI-driven platforms can swiftly identify viable drug targets and design novel molecules with a higher probability of success. Insilico Medicine's February 2025 "Preclinical Drug Discovery Benchmarks" announcement, for instance, highlighted their average 13-month timeline to nominate preclinical candidates, a substantial improvement over the traditional 2.5 to 4-year process. Real-world applications further validate these technological advancements, with AstraZeneca's March 2025 findings at the European Lung Cancer Congress showcasing an AI-powered chest X-ray tool that achieved a 54.1% positive predictive value, underscoring AI's capacity to enhance diagnostic precision and clinical trial screening efficiency.

Market Challenge

A significant impediment to the growth of the Global Artificial Intelligence in Precision Medicine Market is the intricate challenge surrounding data privacy and security. Precision medicine inherently relies on aggregating vast, diverse datasets-including genomic sequences, electronic health records, and real-time patient monitoring data-to effectively train complex AI algorithms. Yet, the extremely sensitive nature of this information mandates strict adherence to rigorous regulatory frameworks, which frequently result in data silos. These silos make it difficult for organizations to legally share the varied datasets essential for validating AI models across different demographic groups, thereby hindering the development of universally applicable algorithms and limiting access to the broad data spectrum needed to minimize bias and ensure clinical accuracy.

The escalating threat of cyberattacks further compounds these difficulties, leading many healthcare providers to hesitate in adopting cloud-based AI solutions. According to the Healthcare Information and Management Systems Society in 2025, a notable 75% of healthcare cybersecurity professionals identified data privacy as a paramount concern regarding the future integration of artificial intelligence in healthcare settings. This widespread apprehension compels institutions to prioritize defensive security measures over innovative AI integration, effectively diverting crucial investment. Consequently, the apprehension surrounding data breaches and their potential legal ramifications directly constrains the market's trajectory by increasing operational costs and extending the timelines required for the commercial deployment of new technologies.

Market Trends

The market for AI in precision medicine is significantly shaped by the expanding adoption of AI-driven radiomics and computational pathology, which are fundamentally transforming diagnostic workflows. These advanced technologies enable the quantitative assessment of complex tissue characteristics that are often imperceptible through subjective human review. By deploying deep learning algorithms to meticulously analyze digitized histological slides and medical images, these tools standardize biomarker quantification and enhance the precision of patient stratification for targeted therapies. This approach uncovers subtle, sub-visual patterns within the tumor microenvironment, thereby reducing inter-observer variability and facilitating more accurate treatment decisions. Proscia's June 2025 "Digital Pathology and AI Highlights from ASCO 2025" report, for instance, detailed a multi-center study where AI-assisted analysis boosted diagnostic agreement among pathologists to 86.4% for HER2-low breast cancer scoring, marking a substantial improvement over traditional manual assessment methods.

Concurrently, a surge in strategic biopharma-tech partnerships and the formation of robust ecosystems are accelerating market growth. Pharmaceutical companies are increasingly collaborating with specialized AI firms to gain access to extensive real-world data and proprietary computational platforms. These strategic alliances streamline the integration of longitudinal clinical datasets with genomic information, fostering resilient ecosystems that both expedite drug discovery and validate precision medicine hypotheses. Rather than building internal capabilities from the ground up, biopharma leaders are leveraging these external technology stacks to efficiently navigate the complexities of multi-omics data and regulatory compliance. Evidence of this trend is seen in Tempus AI's January 2026 "Preliminary 2025 Financial Results" announcement, which reported a total contract value exceeding $1.1 billion and the establishment of over 70 data agreements, underscoring the rapid commercial validation and operational reliance on these collaborative data ecosystems.

Key Market Players

• Glanbia Plc
• BioXcel Therapeutics, Inc.
• Sanofi S.A.
• NVIDIA Corp.
• Alphabet Inc.
• IBM Technology corporation
• Microsoft Corporation
• Intel Corp.
• AstraZeneca plc
• GE HealthCare Technologies Inc.
• Enlitic, Inc.

Report Scope

In this report, the Global Artificial Intelligence In Precision Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Artificial Intelligence In Precision Medicine Market, By Technology

• Deep Learning
• Querying Method
• Natural Language Processing
• Context-Aware Processing

Artificial Intelligence In Precision Medicine Market, By Component

• Hardware
• Software
• Service

Artificial Intelligence In Precision Medicine Market, By Therapeutic Application

• Oncology
• Cardiology
• Neurology
• Respiratory
• Other

Artificial Intelligence In Precision Medicine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Artificial Intelligence In Precision Medicine Market.

Available Customizations:

Global Artificial Intelligence In Precision Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).